MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from initial
public offering, net of...
$349,031K
Proceeds from issuance of
common stock under...
$277K
Net cash provided by
financing activities
$349,308K
Net increase in
cash, cash...
$56,290K
Canceled cashflow
$293,018K
Proceeds from maturities
of marketable...
$104,000K
Accounts payable
$5,324K
Depreciation expense
$5,214K
Stock-based compensation
expense
$2,777K
Other assets
-$2,700K
Net cash used in
investing activities
-$203,217K
Net cash used in
operating activities
-$89,801K
Canceled cashflow
$104,000K
Canceled cashflow
$16,015K
Purchase of marketable
securities
$306,955K
Net loss
-$82,958K
Accrued expenses and
other current...
-$15,065K
Purchase of property and
equipment
$262K
Prepaid expenses and
other current assets
$4,377K
Operating lease
liabilities
-$2,488K
Amortization of premiums and
accretion of discounts on...
$827K
Amortization of operating
lease right-of-use...
$101K
Back
Back
Cash Flow
Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc. (EIKN)
source: myfinsight.com